Paul F. Howley

Former Research Director at Bavarian Nordic A/S

Paul F. Howley

Paul F. Howley

Former Research Director at Bavarian Nordic A/S

Biography

Paul F. Howley is former Technical Director at Prescient Therapeutics Ltd., former Research Director at Bavarian Nordic An and former Director-Virology & Protein Chemistry at Sentinext Therapeutics Sdn. Bhd. He received an undergraduate degree from The University of Reading.

Overview
RelSci Relationships

55

Relationships
RelSci Relationships are individuals Paul F. Howley likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Bavarian Nordic A/S

Relationship likelihood: Average

Consultant, Production & Process Development Director at Sentinext Therapeutics Sdn. Bhd.

Relationship likelihood: Average

Chief Executive Officer at Austrianova Singapore Pvt Ltd.

Relationship likelihood: Average

Former Chief Executive Officer & Development Director at Prescient Therapeutics Ltd.

Relationship likelihood: Average

Head, Life Sciences & Healthcare Practice at Cappello Global LLC

Relationship likelihood: Average

Former Chief Financial Officer, Secretary & Director at Prescient Therapeutics Ltd.

Relationship likelihood: Average

Vice President-Clinical Operations at Prescient Therapeutics Ltd.

Relationship likelihood: Average

Former Executive Chairman at Prescient Therapeutics Ltd.

Relationship likelihood: Average

Former Medical Director at Sentinext Therapeutics Sdn. Bhd.

Relationship likelihood: Average

Acting Chief Financial Officer at Valneva SE

Relationship likelihood: Average

Paths to Paul F. Howley
Potential Connections via
Relationship Science
You
Paul F. Howley
Former Research Director at Bavarian Nordic A/S
Education
Class of 1985

The University of Reading

Career History
Technical Director
2002 - 2008

Prescient Therapeutics Ltd. is a biopharmaceutical company. The firm engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded on May 22, 1986 and is headquartered in South Melbourne, Australia.

Research Director
1998 - 2002

Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer. Its products include IMVAMUNE for Ebola, HPV, HBV, and HIV diseases. The company was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Director-Virology & Protein Chemistry
Prior

Sentinext Therapeutics Sdn. Bhd. develops vaccines and therapeutics for tropical infectious diseases. Its pharmaceutical research and development focuses on EV71, polio, influenza and dengue diseases. The company was founded by Mary Jane Cardosa and Peter Samuel Wulff in 2009 and is headquartered in Penang, Malaysia.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Paul F. Howley. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Paul F. Howley's profile does not indicate a business or promotional relationship of any kind between RelSci and Paul F. Howley.